PCM
ALLO icon

Penserra Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Penserra Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-28,284
Closed -$89K – 1245
2023
Q3 		$89K Buy
28,284
+7,109
+34% +$31.2K ﹤0.01% 914
2023
Q2 		$105K Buy
21,175
+3,065
+17% +$16.6K ﹤0.01% 928
2023
Q1 		$89K Buy
18,110
+4,890
+37% +$31.4K ﹤0.01% 783
2022
Q4 		$83K Sell
13,220
-4,052
-23% -$37.5K ﹤0.01% 831
2022
Q3 		$186K Buy
17,272
+11,732
+212% +$159K 0.01% 652
2022
Q2 		$63K Sell
5,540
-1,736
-24% -$15.4K ﹤0.01% 857
2022
Q1 		$66K Buy
+7,276
New +$75.8K ﹤0.01% 939
2021
Q4 		– Sell
-3,255
Closed -$83K – 1358
2021
Q3 		$83K Buy
3,255
+35
+1% +$831 ﹤0.01% 869
2021
Q2 		$83K Buy
3,220
+40
+1% +$1.14K ﹤0.01% 849
2021
Q1 		$112K Sell
3,180
-60
-2% -$2.02K ﹤0.01% 669
2020
Q4 		$81K Buy
3,240
+2,052
+173% +$66.9K ﹤0.01% 617
2020
Q3 		$44K Buy
+1,188
New +$44.8K ﹤0.01% 640

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Penserra Capital Management's ALLO Position: Q4 2023 in Review

Penserra Capital Management sold out of Allogene Therapeutics (ALLO) in Q4 2023, closing a stake of 28,284 shares — an estimated $89K sold.

Penserra Capital Management first reported a position in ALLO in Q3 2020 and held it in 12 quarters. The position peaked at $186K in Q3 2022. 170 funds tracked by Wall St. Rank hold ALLO as of Q4 2023.

  • Penserra Capital Management reported no remaining Allogene Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Penserra Capital Management sold 28,284 Allogene Therapeutics shares in Q4 2023, an estimated $89K.
  • Penserra Capital Management first reported a position in Allogene Therapeutics in Q3 2020 and held it in 12 quarters.
  • Penserra Capital Management's Allogene Therapeutics position peaked at $186K in Q3 2022.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2023.

Based on Penserra Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.